Assessment of Disease Activity in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus: A Companion to Rheumatology

Volumn , Issue , 2007, Pages 19-23

  Mosca, Marta ^a   Merrill, Joan T ^b   Bombardieri, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 65449183283     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04434-9.50007-5     Document Type: Chapter

References (46)

1. Lehmann E. Practicable and valid approach to evaluate the efficacy of nootropic drugs by means of rating scales. Pharmacopsychiatry 1984, 17:71-75.
2. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992, 19:53-59.
3. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005, 19:685-708.
4. Ramsey-Goldman R, Isenberg DA Systemic lupus erythematosus measures. Arthritis Care Res 2003, 49(Suppl 5):S225-S233.
5. Haq I, Isenberg DA How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice?. Best Pract Res Clin Rheumatol 2002, 16:181-194.
6. Symmons DPM, Coppock JS, Bacon PA, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Q J Med 1988, 69:927-937.
7. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993, 86:447-458.
8. Liang MH, Socher SA, Larson MG, Schur PH Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989, 9:1107-1118.
9. Stoll T, Stucki G, Malik J, et al. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996, 55:756-760.
10. Ward MM, Marx AS, Barry NN Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000, 27:664-670.
11. Gordon C, Sutcliffe N, Skan J, et al. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 2003, 42:1372-1379.
12. Isenberg DA Gordon C on behalf of the BILAG Group From BILAG to BLIPS-disease activity assessment in lupus past, present and future. Lupus 2000, 9:651-654.
13. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005, 44:902-906.
14. Marks SD, Pilkinton C, Woo P, Dillon MJ The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus. Rheumatology 2004, 43:1186-1189.
15. Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. Clin Exp Rheumatol 1992, 10:527-539.
16. Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992, 10:541-547.
17. Bencivelli W, Vitali C, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerized clinical chart and its application to the comparison of different indices of disease activity. Clin Exp Rheumatol 1992, 10:549-554.
18. Bombardieri S, Vitali C, Caponi L, et al. Activity criteria in systemic lupus erythematosus. Clin Exp Rheumatol 1994, 12(Suppl. 11):45-48.
19. Mosca M, Neri R, Giannessi S, et al. The inter-observer variability of the ECLAM index in the evaluation of disease activity in systemic lupus erythematosus (abstract). Arthritis Rheum 1999, 42(Suppl 9):S98.
20. Mosca M, Bencivelli W, Vitali C, et al. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000, 9:445-450.
21. Brunner HI, Silverman ED, Bombardier C, Feldman BM European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2003, 15(3):335-341. 49.
22. Ruperto N, Ravelli A, Cuttica R, et al. The Pediatric Rheumatology International Trials Organization Criteria for the Evaluation of Response to Therapy in Juvenile Systemic Lupus Erythematosus. Prospective validation of the Disease Activity Core Set. Arthritis Rheum 2005, 52:2854-2864.
23. Doria A, Cutolo M, Ghirardello A, et al. Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. Arthritis Rheum 2002, 47:202-209.
24. Mosca M, Bencivelli W, Della Casa-Alberighi O, et al. The validity of a computerized clinical chart (ACTICARD) for the retrospective calculation of the ECLAM index (abstract). Lupus 2001, 10(Suppl 1).
25. Bae SC, Koh HK, Chang DK, et al. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001, 10:405-409.
26. Parodi A, Massone C, Cacciapuoti, et al. Measuring the activity of the disease in patients with cutaneous lupus erythematosus. Br J Dermatol 2000, 142:457-460.
27. Abrahamowicz M, Fortin PR, du Berger R, et al. The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rheumatol 1998, 25:277-284.
28. Fortin PR, Abrahamowicz M, Neville C, et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 1998, 7:101-107.
29. Ward MM, Marx AS, Barry NN Psychological distress and changes in the activity of systemic lupus erythematosus. Rheumatology 2002, 41:184-188.
30. Ramsey-Goldman R, Manzi S, Schilling EM, et al. Lupus activity in pregnant and non-pregnant patients. Arthritis Rheum 1995, 38:S219. Suppl.
31. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992, 6:630-640.
32. Gladman DD, Goldsmith CH, Urowitz MB, et al. Cross-cultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 1992, 19:608-611.
33. Hawker G, Gabriel S, Bombardier C, et al. A reliability study of SLEDAI, a disease activity index for systemic lupus erythematosus. J Rheumatol 1993, 20:657-660.
34. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992, 19:53-59.
35. Gladman DD, Goldsmith CH, Urowitz MB, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: Internal validation. J Rheumatol 1994, 21:1468-1471.
36. Gladman DD, Ibanez D, Urowitz MB Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002, 29:288-291.
37. Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992, 19:1551-1558.
38. Buyon JP, Kalunian KC, Ramsey-Goldman R, et al. Assessing disease activity in SLE patients during pregnancy. Lupus 1999, 8:677-684.
39. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence and clinical description of flare in systemic lupus erythematosus. Arthritis Rheum 1991, 8:937-944.
40. Gladman DD, Urowitz MB, Kagal A, Hallet D. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000, 27:377-379.
41. Arce-Salinas A, Cardiel MH, Guzman J, Alcocer-Varela J. Validity of retrospective disease activity assessment in systemic lupus erythematosus. J Rheumatol 1996, 23:846-849.
42. Urowitz MB, Gladman DD, Tozman ECS, Goldsmith CH The Lupus Activity Criteria Count (LACC). J Rheumatol 1984, 11:783-787.
43. Ruiz-Irastorza G, Khamashta MA, Gordon C, et al. Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale. Arthritis Rheum 2004, 51:78-82.
44. Strand V, Gladman DD, Isenberg DA, et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999, 26:490-497.
45. Strand V, (for the OMERACT SLE Steering Committee), Gladman D, Isenberg D, et al. Endpoints: consensus recommendations from OMERACT IV. Lupus 2000, 9:322-327.
46. American College of Rheumatology Ad Hoc Committe on Systemic Lupus Erythematosus Response Criteria The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2004, 50:3418-3426.